Hemostemix Inc. announced that it has contracted two additional clinical research associates, is completing the remaining data entry and source document verifications, and has subscribed with GlobeX Data Ltd., to encrypt its email communications with regulatory authorities in a secure portal. Sekur is one app that bundles encrypted email, messaging and file transfer into one solution that incorporates unlimited sized attachments, data loss prevention, anti-phishing, a self-destruct timer and privacy features. Sekur emails between senders and recipients never leave GlobeX's encrypted servers based in Switzerland.

In connection with the Offering that closed on December 18, 2020 the Company inadvertently failed to compensate two finders who assisted with the private placement for gross proceeds of $1,272,117. The Corporation will pay the finders a cash finder's fee of $60,249.36 and issue finder's options entitling the finders to purchase 261,247 units of the Corporation at a price of $1.00 within 12 months of the original closing date. Each unit is comprised of one common share and one purchase warrant, with each warrant entitling the holder to acquire one common share at a price of $1.00 within 12 months of the closing date.

On October 21, 2019, the Company announced the results from its Phase II multi-center randomized double-blind placebo- controlled clinical trial of ACP-01 in critical limb ischemia (CLI) abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.